In connection with the Tranaction, Mr. Kistler, our sole
employee, executive officer, director and our Principal
Executive Officer, Principal Financial Officer and Principal
Accounting Officer, shall resign all such positions with the
Company immediately following the Boards appointment of Michael
T. Redman as a director to our Board and as our Chief Executive
Officer, President, Principal Executive Officer and Principal
Financial Officer and J. Donald Payne as a director to our
Board and our Secretary and Chief Accounting Officer. Mr.
Redman is currently the Chief Executive Officer, President and
a Director and Mr. Payne is the Senior Vice President Finance
and Administration and Secretary of the Purchaser.

Prior to the SPA Closing, neither Mr. Redman nor Mr. Payne will
be officers and/or directors of the Company, did not hold any
previous position with the Company nor have they been involved
in any transactions with the Company or any of our directors,
executive officers, affiliates or associates that are required
to be disclosed to the rules and regulations of the SEC.
Moreover, neither of such persons has been the subject of any
bankruptcy petition filed by or against any business of which
he was a general partner or executive officer either at the
time of the bankruptcy or within two years prior to that time,
been convicted in a criminal proceeding or been subject to a
pending criminal proceeding (excluding traffic violations and
other minor offenses), been subject to any order, judgment or
decree, not subsequently reversed, suspended or vacated, of any
court of competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his
involvement in any type of business, securities or banking
activities or been found by a court of competent jurisdiction
(in a civil action), the SEC or the Commodity Futures Trading
Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed,
suspended or vacated.

Michael T. Redman

Mr. Redman created and named Oncolix from technology acquired
from the Greenville Hospital System, the current majority
shareholder of Oncolix. Since joining Oncolix, Mr. Redman, on
behalf of the Company, has prepared business plans, presented
at major life science conferences and has been primarily
responsible for the Company having had issued eight US patents
and additional foreign patents. Under Mr. Redmans guidance, the
Company has raised more than $15 million in financing, licensed
a proprietary expression system required to manufacture the
Companys lead drug, solved manufacturing challenges, hired key
personnel and took one oncology drug from research stage
through Phase II (melanoma) and a second drug from the
preclinical development to Phase I clinical trials (ovarian
cancer), and successfully obtained orphan designation from the
FDA for such drug. Mr. Redman has extensive contacts in the
investment community, both domestically and internationally,
large pharmaceutical companies, contract research organizations
(both domestically and internationally) and research
institutions for sponsored research (including MD Anderson
Cancer Center). Prior to forming Oncolix, Mr. Redman was the
CEO

of Bone Medical in Australia and the CEO and co-founder of
Opexa Pharmaceuticals, which commenced operations in February
of 2001 and was sold to PharmaFrontiers Corporation in November
2004. Mr. Redman also acts as an interim CEO to Onco CNS, a
small private start up that he advises on his own time. In
addition to the above CEO positions, Mr. Redman also has held
key management positions with Zonagen, Aronex Pharmaceuticals,
Biovail, and American Home Products. Mr. Redman is an active
member of the Licensing Executives Society and formerly served
on its Executive Committee. Mr. Redman earned a BA in Biology
from the University of Missouri and a Masters in Business
Administration from the University of Phoenix.

J. Donald Payne

Mr. Payne has served as the Senior Vice President – Finance and
Administration and Secretary of Oncolix since 2011. In such
capacity, he has been responsible for assisting with managing
the clinical and manufacturing operations of Oncolix as well as
handling regulatory filings and intellectual property matters.
His time devoted to Oncolix has fluctuated since 2011 depending
on the activities of Oncolix. Mr. Payne also currently is the
Co-Founder, President and Director of AuroRad, Inc., an
unaffiliated start-up that intends to develop radiation
oncology products. Until June 2012, Mr. Payne was a Director
and Chairman of the Audit Committee of Pressure Biosciences,
Inc., a Nasdaq-listed life science instrumentation company.
Previously, Mr. Payne held various senior management positions
at Nanospectra Biosciences, Sensus Drug Development, LifeCell
Corporation, Aprogenex and Entex Energy. His financial
experience includes initial public offerings on the New York
and American Stock Exchanges and various public and private
offerings. Mr. Payne has co-authored 9 scientific publications
and is a co-inventor of 2 issued patents. Mr. Payne is a Summa
Cum Laude graduate of Rice University with a Masters in
Business Administration (1992) and a Summa Cum Laude graduate
of Texas AM University (1976) with a Bachelor in Business
Administration. He is a licensed certified Public Accountant in
Texas (1978).